Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
F-star Therapeutics Inc.
Headquarters: Cambridge, United Kingdom
Website: N/A
Year Founded: 2006
Status: Acquired
BioCentury | Nov 15, 2024
Management Tracks
Howard Hechler named CEO of Lumicell
Plus: Veronica Fonck becomes chair of MinervaX, and updates from Grey Wolf, Actimed and Caszyme
BioCentury | Oct 17, 2023
Deals
Oct. 17 Quick Takes: Monte Rosa gets $50M in molecular glue deal with Roche
Plus: Gilead options Assembly’s antiviral pipeline and updates from KKR, Catalio, Roche, SpliceBio, VedaBio, Merck, Nuvalent, Tessellate, Amplifier and Evelo
BioCentury | Sep 14, 2023
Management Tracks
DNAnexus names Laur as CEO
Plus: Ports now CSO at Cargo and updates from Protalix, Culture, 4D, DiaMedica, Likarda, Precise, Pixelgen and Oviva
BioCentury | May 18, 2023
Management Tracks
Roche’s Perettie to head cell therapy at Kite
Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIG
BioCentury | Mar 8, 2023
Regulation
March 7 Quick Takes: Protagonist crosses $1B in market cap as shares rise on psoriasis data
Plus: At last, CFIUS clears F-star acquisition and updates from Shorla, Chiesi, Affibody, Ionis, AZ, BioMarin
BioCentury | Dec 20, 2022
Regulation
Dec. 20 Quick Takes: Verona lining up COPD submission after second Phase III readout
Plus: F-star takeout remains in CFIUS limbo and updates from Seagen, Astellas, Merck, Catalyst, Eisai and more
BioCentury | Nov 3, 2022
Deals
Nov. 2 Quick Takes: CSL paying $200M for Arcturus’ mRNA vaccine tech
Plus Rubius seeking alternatives and updates from Horizon, Lilly-Innovent, GSK, Compass, Regeneron, Exelixis, CFIUS and more
BioCentury | Sep 21, 2022
Deals
Sept. 20 Quick Takes: Rocket gains gene therapy via Renovacor takeout
Plus Theravance buying out GSK and updates from ImmunoScape, Sentynl, Pfizer and more
BioCentury | Jul 28, 2022
Management Tracks
CEO Li Yi resigns from Sino
Plus Sekhri becomes CEO of vTv and updates from Eisai, Summit and more
BioCentury | Jul 8, 2022
Deals
F-star suitor slashed bid as internal confidence sank in clinical programs
Tetravalent antibody developer acknowledged difficult fund-raising environment, reassessed clinical programs’ probability of success
Items per page:
1 - 10 of 32